Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.61 |
| ▸ | FLT1 | P17948 | 4/20 | 0.61 |
| ▸ | RET | P07949 | 3/20 | 0.61 |
| ▸ | FLT4 | P35916 | 2/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548727 | 0.85 | KDR (0.78) | KDRFLT1RETFLT4PDGFRB | |
| SCHEMBL2748909 | 0.83 | KDR (0.67) | KDRFLT1RETFLT4PDGFRB | |
| SCHEMBL273582 | 0.83 | KDR (0.63) | KDRFLT1RETFLT4PDGFRB | |
| SCHEMBL4548726 | 0.78 | KDR (0.75) | KDRFLT1RETFLT4PDGFRB | |
| SCHEMBL2435244 | 0.78 | KDR (0.71) | KDRFLT1RETFLT4PDGFRB | |
| SCHEMBL2747307 | 0.78 | KDR (0.75) | KDRFLT1RETFLT4PDGFRB | |
| SCHEMBL5740759 | 0.78 | KDR (0.59) | KDRFLT1RETFLT4PDGFRB | |
| SCHEMBL4548725 | 0.77 | KDR (0.71) | KDRFLT1RETFLT4PDGFRB | |
| SCHEMBL4548840 | 0.77 | KDR (0.80) | KDRFLT1 | |
| SCHEMBL2748156 | 0.76 | KDR (0.76) | KDRFLT1RETFLT4PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | disclosed |
| US-8026247-B2 | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | NOVARTIS AG | 2008-12-11 | — | — | US | disclosed |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | KDR, FLT4, FLT1 | KDR 1/4885FLT1 3/4885RET 198/4885 |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | KDR 826/4885FLT1 638/4885RET 371/4885 |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | MAP3K20, MAP3K1, MAP3K19 | KDR 888/4885FLT1 678/4885RET 385/4885 |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | KDR, FLT4, FLT1 | KDR 1/4885FLT1 3/4885RET 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.